PD1-induced Shp2 condensation organizes inhibitory signalosomes through selective substrate partitioning

This study reveals that PD1 engagement triggers Shp2 to undergo liquid-liquid phase separation, forming dynamic condensates that selectively partition inhibitory substrates like CD3{zeta} and CD28 to organize signalosomes and suppress T cell activation.

The Gist

The Big Picture: The "Off Switch" That Builds a Factory

Imagine your immune system is a highly trained army (T-cells) designed to fight off invaders like cancer. However, sometimes this army gets too aggressive and might attack healthy tissue. To keep things in check, the body has "brakes" called PD-1. When PD-1 hits its target (a ligand), it tells the T-cell, "Slow down, stand down."

For a long time, scientists knew PD-1 worked, but they didn't know how it physically stopped the T-cell. This paper reveals that PD-1 doesn't just send a chemical message; it actually builds a temporary, liquid factory right on the surface of the cell to do the job.

The Main Characters

1. PD-1: The "Brake Pedal" on the T-cell.
2. Shp2: The "Mechanic" or "Scissor" that cuts the wires keeping the T-cell active.
3. The Substrates (CD3ζ/CD28): The "Wires" or "Fuel lines" that keep the T-cell engine running.
4. LLPS (Liquid-Liquid Phase Separation): The process of forming a liquid droplet (like a drop of oil in water) that acts as a specialized workspace.

---

The Story: How the "Liquid Factory" Works

1. The Trigger: Putting the Brake on

When a T-cell meets a cancer cell, the PD-1 "brake" on the T-cell grabs onto its partner. This is like pressing the brake pedal in a car. But instead of just stopping the car, this action triggers a magical transformation.

2. The Transformation: From Solitary to Social

Normally, the mechanic (Shp2) is sitting alone, locked in a box (a closed shape), unable to work. But when PD-1 grabs it, the box opens up. Suddenly, the mechanics realize they can hold hands and stick together.

In the lab, the scientists found that these mechanics don't just stick together; they clump into a liquid droplet. Think of it like raindrops merging on a windowpane. These droplets are dynamic—they flow, they merge, and they bounce around. This is called Phase Separation.

3. The Magic Ingredient: The Scissors Must Move

Here is the coolest part: The liquid nature of this droplet depends on the mechanic actually working.

• The mechanic (Shp2) is a pair of scissors that cuts chemical tags off the T-cell's "wires."
• If you break the scissors (make them unable to cut), the liquid droplet turns into a solid gel. It stops flowing and gets stuck.
• Analogy: Imagine a group of people dancing in a circle. As long as they are moving (cutting the wires), the circle flows like liquid. If they freeze (can't cut), the circle becomes a rigid, solid statue. The paper shows that the act of cutting keeps the "factory" fluid and efficient.

4. The Sorting Hat: Who Gets In?

Once this liquid factory forms, it acts like a VIP club with a very strict bouncer.

• The VIPs (CD3ζ and CD28): These are the "wires" that tell the T-cell to attack. The factory loves these. It pulls them inside the liquid droplet so the scissors can cut them immediately.
• The Bouncers (TIGIT): This is another receptor, but it doesn't get invited in. The factory ignores it.
• Why? The factory seems to sort things based on electric charge. The "wires" that need cutting have a positive charge (like a magnet), and the liquid factory is negatively charged, so it attracts them. It's like a magnet pulling in iron filings while ignoring plastic.

5. The Result: A Super-Efficient Shutdown

Because the factory gathers all the "wires" (CD3ζ) into one liquid bubble right next to the scissors (Shp2), the T-cell gets shut down incredibly fast and efficiently. It's much faster than if the scissors had to wander around the cell looking for the wires.

What Happens When the System Breaks?

The scientists created a mutant version of the mechanic (Shp2) that couldn't form these liquid droplets (it couldn't hold hands).

• In the Lab: Without the liquid factory, the "wires" weren't cut as fast.
• In Mice: When they put these broken mechanics into mice with tumors, the T-cells didn't slow down enough. The mice's immune systems fought the cancer much better.

Why Does This Matter?

This discovery changes how we think about immune checkpoints.

1. It's not just chemistry; it's physics. The immune system uses the laws of physics (liquid droplets) to organize its signals.
2. New Drug Targets: Currently, we try to block PD-1 with antibodies to stop the "brake." But this paper suggests we could also design drugs that break the liquid factory. If we can stop the "liquid droplet" from forming, we can stop the T-cell from being turned off, helping the immune system fight cancer more effectively.

Summary Analogy

Imagine a busy highway (the T-cell) that needs to be stopped.

• Old View: The traffic cop (PD-1) just waves a hand, and cars slow down one by one.
• New View: The traffic cop calls in a mobile traffic jam (the liquid droplet). This jam instantly traps all the fast cars (the "attack" signals) in a specific zone where a demolition crew (Shp2) can quickly dismantle their engines. If the demolition crew stops working, the traffic jam turns into a solid, useless pile of cars, and the highway stays open.

This paper proves that the immune system uses these "liquid traffic jams" to control its power, and breaking the jam could be the key to curing cancer.

Technical Summary

1. Problem Statement

Programmed cell death protein 1 (PD1) is a critical immune checkpoint receptor that suppresses T cell activation to maintain homeostasis and prevent autoimmunity. Upon binding its ligands (PD-L1/PD-L2), PD1 recruits the phosphatase Shp2 to dephosphorylate signaling molecules, thereby inhibiting T cell responses. A hallmark of PD1 engagement is the formation of microclusters (nanoscale assemblies) at the immune synapse. However, the physical mechanisms driving these clusters and their functional significance in organizing the inhibitory signalosome have remained unclear. Specifically, it was unknown whether Liquid-Liquid Phase Separation (LLPS) plays a role in PD1 signaling, how Shp2's enzymatic activity relates to its spatial organization, and how these structures achieve substrate selectivity.

2. Methodology

The authors employed a multi-disciplinary approach combining biochemical reconstitution, live-cell imaging, and functional immunological assays:

• In Vitro Reconstitution: Purified recombinant human/mouse Shp2 and PD1 intracellular domains (ICD) were mixed with crowding agents (PEG) to induce phase separation. Turbidity measurements (OD600) and confocal microscopy were used to characterize droplet formation, fusion, and fluorescence recovery after photobleaching (FRAP).
• Cell-Supported Lipid Bilayer (SLB) Assays: Jurkat T cells (PD1/Shp2 double knockout) were engineered to express fluorescently tagged PD1 and Shp2 variants. These cells were stimulated on SLBs presenting PD-L1 and anti-CD3 antibodies to visualize microcluster dynamics, fusion events, and FRAP kinetics in a near-physiological membrane environment.
• Mutagenesis: Key mutations were introduced to test specific hypotheses:
  • REKE: Charge-reversal mutations (R362E/K364E) in the Shp2 PTPase domain to disrupt electrostatic self-association (LLPS) without affecting catalytic activity.
  • C459E: A catalytically dead Shp2 mutant.
  • FF: Tyrosine-to-phenylalanine mutations in PD1 ITIM/ITSM motifs to prevent phosphorylation.
• Substrate Partitioning Assays: Pre-formed condensates were mixed with various ICDs (CD3ζ, CD28, TIGIT) and charge-modified GFP variants to test electrostatic selectivity.
• Proximity Ligation Assay (PLA): Used in cells to quantify the physical proximity between PD1 and specific receptors (CD3ζ, CD28, TIGIT) in the presence of WT or LLPS-deficient Shp2.
• Functional Assays:
  • In Vitro Kinetics: Measured dephosphorylation rates of DiFMUP and CD3ζ substrates.
  • Cytokine Secretion: Measured IL-2 (Jurkat:Raji coculture) and IFNγ (P14 T cells:DC2.4) to assess T cell inhibition.
  • In Vivo Tumor Model: Adoptive T cell transfer (ACT) into B16-gp33 melanoma-bearing mice to test anti-tumor immunity.

3. Key Contributions & Results

A. PD1 Microclusters are Dynamic Liquid Condensates

• Live-cell imaging and FRAP assays revealed that PD1 microclusters exhibit liquid-like properties, characterized by rapid fusion events and fast fluorescence recovery (τ ~13.5s for PD1, ~8.3s for Shp2).
• This liquidity depends on the interaction between phosphorylated PD1 (pPD1) and Shp2.

B. Mechanism of LLPS: Electrostatic Self-Association

• Trigger: Ligand binding phosphorylates PD1, which recruits Shp2. pPD1 binding induces a conformational change in Shp2 from a closed (autoinhibited) to an open state.
• Driver: This open state exposes basic patches (R362/K364) on the Shp2 PTPase domain, enabling electrostatic self-association (trans-interactions) that drives LLPS.
• Evidence:
  • Condensates form only when pPD1 and Shp2 are mixed.
  • High salt concentrations (disrupting electrostatics) dissolve condensates.
  • The REKE mutation (disrupting the basic patch) abolishes condensate formation in vitro and in cells, despite Shp2 retaining its ability to bind pPD1.

C. Catalytic Activity Regulates Condensate Liquidity

• While Shp2 binding initiates condensation, its catalytic activity is required to maintain the liquid state.
• Catalytically dead Shp2 (C459E) forms condensates with pPD1, but these are solid/gel-like (no FRAP recovery).
• Mechanism: Shp2 dephosphorylates pPD1, breaking the pY-SH2 bonds that hold the network together. This "turnover" prevents the condensate from solidifying, allowing dynamic exchange with the cytoplasm.

D. Selective Substrate Partitioning (The "Signalosome")

• PD1:Shp2 condensates act as biochemical microreactors that selectively enrich specific substrates based on electrostatic properties and structural motifs.
• Enrichment: Positively charged ICDs of CD3ζ and CD28 are strongly enriched within the condensates.
• Exclusion: The ICD of the inhibitory receptor TIGIT (and negatively charged proteins) is largely excluded.
• Functional Consequence: This partitioning accelerates the dephosphorylation of CD3ζ. In LLPS conditions, WT Shp2 dephosphorylates CD3ζ significantly faster than the REKE mutant. The REKE mutant, while catalytically active in dilute solution, fails to efficiently dephosphorylate substrates in the cellular context because it cannot co-compartmentalize them.

E. Physiological and In Vivo Impact

• Clustering: Disrupting Shp2 LLPS (via REKE mutation) significantly reduces PD1 microcluster intensity and size in cells.
• Inhibition: Cells expressing Shp2-REKE show reduced PD1-mediated inhibition of T cell activation (higher IL-2 and IFNγ secretion upon PD1 engagement).
• In Vivo: In a melanoma mouse model, T cells expressing Shp2-REKE exhibited enhanced anti-tumor immunity compared to WT Shp2 cells, effectively "weakening" the PD1 checkpoint. This confirms that Shp2 LLPS is essential for full PD1 inhibitory function in vivo.

4. Significance

• Paradigm Shift: This study establishes LLPS as an intrinsic organizing principle of the PD1 inhibitory pathway. It moves beyond the view of PD1 signaling as a simple linear cascade to a spatially organized, phase-separated event.
• Mechanistic Insight: It reveals a unique feedback loop where enzymatic activity (dephosphorylation) regulates the material state (liquidity) of the signaling complex, ensuring reversibility and dynamic control.
• Therapeutic Implications: The findings suggest that targeting the material properties (e.g., electrostatic interfaces) or phase separation of immune checkpoint complexes could be a novel strategy to modulate T cell immunity. Disrupting Shp2 LLPS could potentially enhance T cell anti-tumor responses without completely blocking the receptor, offering a new avenue for cancer immunotherapy.
• Evolutionary Context: The study notes that human PD1 induces Shp2 condensation more efficiently than murine PD1, highlighting species-specific differences in checkpoint regulation that are crucial for translating mouse data to human clinical settings.

In summary, the paper demonstrates that PD1 engagement licenses Shp2 to undergo liquid-liquid phase separation, creating dynamic condensates that selectively concentrate activating substrates (CD3ζ/CD28) while excluding others, thereby optimizing the efficiency of immune suppression.